Retatrutide for obesity: separating early trial data from TikTok hype

What did @dr_hammmad actually say?

Honestly, this is a difficult video to fact-check because the available transcript is not a reliable rendering of what was spoken. The caption is in Arabic and references retatrutide (ريتاتروتايد), a next-generation triple-agonist weight-loss drug currently in Phase 3 trials. The transcript provided appears to be a machine-translation artifact, producing English sentences that do not correspond to any coherent medical claims. What we can work with is the hashtag context: obesity (سمنة), a Saudi city geo-tag (الدمام_الخبر), and the drug name itself.

Given that context, this video is almost certainly a discussion of retatrutide as a weight-loss intervention, likely framed around its mechanism or availability. We are assessing what is publicly known about that drug and what responsible communication around it looks like.

Does the science back this up?

Retatrutide has genuinely impressive Phase 2 data, but it is not approved anywhere in the world as of mid-2025. The enthusiasm is understandable. The clinical evidence needs context.

A 2023 Phase 2 trial published in The New England Journal of Medicine (Jastreboff et al., 2023) showed participants on the highest dose (12 mg weekly) lost a mean of 24.2% of body weight over 48 weeks. That number is striking. For comparison, semaglutide 2.4 mg (Wegovy) produced around 14.9% in the STEP 1 trial (Wilding et al., 2021, NEJM). Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously, which is why the weight loss signal is larger than dual agonists like tirzepatide.

However, Phase 2 trials are not Phase 3. Sample sizes are smaller, follow-up periods are shorter, and cardiovascular outcome data do not yet exist for this drug. The gastrointestinal side effect profile was also significant: nausea and vomiting were common, particularly during dose escalation.

What did they get wrong (or right)?

Because the transcript does not yield usable quotes, we cannot attribute specific errors to this creator. What we can say is that any TikTok video promoting retatrutide to a general Arabic-speaking audience in 2025 carries real risks if it omits the following points.

• Retatrutide is not approved by the FDA, EMA, or SFDA (Saudi Food and Drug Administration). Any version currently circulating is either compounded or gray-market, and quality control is not guaranteed.
• The 24% weight loss figure from Jastreboff et al. comes from a controlled trial with intensive monitoring. Real-world results without that structure will differ.
• The drug's glucagon receptor agonism distinguishes it from semaglutide and tirzepatide in ways that are not fully characterized yet, particularly for people with diabetes or metabolic liver disease.

If the creator gave accurate information about the drug's mechanism and clearly stated its unapproved status, that would be responsible. If the framing suggested this is something viewers should simply obtain and use, that would be a problem.

What should you actually know?

Retatrutide is one of the more promising obesity drugs in the pipeline, and that is not hype, it is what the Phase 2 data show. But promising pipeline drugs fail in Phase 3 more often than they succeed. The history of anti-obesity pharmacology is littered with drugs that looked excellent in early trials and were later withdrawn for cardiovascular or psychiatric safety signals.

For patients in Saudi Arabia or the Gulf region specifically, accessing unapproved peptides or investigational drugs carries legal and medical risk. The SFDA has not authorized retatrutide, and compounded or imported versions have no verified potency or sterility standards.

If you are considering any GLP-1 class therapy for weight management, the right pathway is a licensed physician evaluation, not a TikTok recommendation. Approved options like semaglutide and tirzepatide have documented safety profiles. Retatrutide does not yet have that record.